Want to see STVN full AI Analyst Report?
STVN Stock Chart & Stats
$15.53
-$0.46(-1.91%)
At close: 4:00 PM EST
$15.53
-$0.46(-1.91%)
Day’s Range― - ―
52-Week Range$12.89 - $28.00
Previous CloseN/A
Volume58.94K
Average Volume (3M)354.30K
Market Cap
$5.39B
Enterprise Value$4.38B
Total Cash (Recent Filing)$112.73M
Total Debt (Recent Filing)$448.52M
Price to Earnings (P/E)33.6
Beta0.88
Next Earnings
Aug 11, 2026EPS Estimate
0.15Next Dividend Ex-DateN/A
Dividend Yield0.29%
Share Statistics
EPS (TTM)0.51
Shares Outstanding49,709,717
10 Day Avg. Volume279,146
30 Day Avg. Volume354,297
Financial Highlights & Ratios
PEG Ratio2.50
Price to Book (P/B)3.15
Price to Sales (P/S)4.10
P/FCF Ratio218.04
Enterprise Value/Market Cap0.81
Enterprise Value/Revenue3.65
Enterprise Value/Gross Profit12.58
Enterprise Value/Ebitda14.88
Forecast
1Y Price Target
$22.00Price Target Upside41.66% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.6
Revenue Forecast (FY)$1.28B
Bulls Say, Bears Say
Bulls Say
Higher Mix Of High-value SolutionsA rising share of high-value solutions (47% of revenue) shifts the business toward higher-margin, program-based supply relationships. This increases recurring, sticky revenue and reduces exposure to commoditized containers, supporting durable margin resilience as capacity utilization improves.
Strong BDS Growth And GLP-1 ExposureRobust BDS demand—driven by syringes, biologics and growing GLP‑1 volumes—reflects structural end‑market growth. Leading product positions in these categories create multi-year contract opportunities and steady organic demand for primary packaging and devices.
Manageable Leverage And Capacity FundingRelatively low leverage (~0.29 D/E) and recent equity growth give the company financial flexibility to fund sizable, growth-oriented capex. This supports execution of multi-year capacity ramps while keeping balance sheet risk within reasonable bounds.
Bears Say
Free Cash Flow Volatility And Slight Negative FCFVolatile and slightly negative free cash flow amid heavy growth capex reduces internal funding capacity and increases reliance on external financing. Over 2–6 months this can constrain strategic flexibility and magnify funding risk if capex remains elevated or demand softens.
Engineering Segment Collapse And Slow Order ConversionA sharp, persistent drop in Engineering revenue and slower customer decision cycles weaken business diversification and delay recovery of high-margin services. Prolonged weakness could depress utilization and prolong the timeline to realize returns from optimization efforts.
Margin Pressure From Depreciation, FX, Tariffs And Higher Tax RateRamp-related depreciation, currency headwinds, tariff costs and an increased tax rate compress gross and net margins. These structural cost burdens can persist through multi-quarter capacity ramps, reducing cash conversion and the pace of margin recovery even as sales grow.
Stevanato Group News
STVN FAQ
What was Stevanato Group Spa’s price range in the past 12 months?
Stevanato Group Spa lowest stock price was $12.89 and its highest was $28.00 in the past 12 months.
What is Stevanato Group Spa’s market cap?
Stevanato Group Spa’s market cap is $5.39B.
When is Stevanato Group Spa’s upcoming earnings report date?
Stevanato Group Spa’s upcoming earnings report date is Aug 11, 2026 which is in 31 days.
How were Stevanato Group Spa’s earnings last quarter?
Stevanato Group Spa released its earnings results on May 07, 2026. The company reported $0.126 earnings per share for the quarter, beating the consensus estimate of $0.118 by $0.008.
Is Stevanato Group Spa overvalued?
According to Wall Street analysts Stevanato Group Spa’s price is currently Undervalued.
Does Stevanato Group Spa pay dividends?
Stevanato Group Spa pays a Annually dividend of $0.062 which represents an annual dividend yield of 0.29%. See more information on Stevanato Group Spa dividends here
What is Stevanato Group Spa’s EPS estimate?
Stevanato Group Spa’s EPS estimate is 0.15.
How many shares outstanding does Stevanato Group Spa have?
Stevanato Group Spa has 49,709,717 shares outstanding.
What happened to Stevanato Group Spa’s price movement after its last earnings report?
Stevanato Group Spa reported an EPS of $0.126 in its last earnings report, beating expectations of $0.118. Following the earnings report the stock price went down -5.108%.
Which hedge fund is a major shareholder of Stevanato Group Spa?
Currently, no hedge funds are holding shares in STVN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Stevanato Group Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.00 (41.66% Upside)
$22.00 (41.66% Upside)
Blogger Sentiment
Bullish
STVN Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 504.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $204.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 4.1%
Last 30 Days ▼ 4.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-24.20%
12-Months-Change
Fundamentals
Return on Equity
9.63%
Trailing 12-Months
Asset Growth
18.58%
Trailing 12-Months
Company Description
Stevanato Group Spa
Stevanato Group S.p.A. is dedicated to engineering, manufacturing, and distributing integrated solutions for the pharmaceutical and healthcare sectors. Its core offerings span a wide array of products, including containment solutions, drug delivery systems, and medical devices, alongside diagnostic and analytical support. The company also produces specialized machinery for tasks such as visual inspection, assembly, packaging, and glass formation. Established in 1949, the company's main operations are situated in Piombino Dese, Italy, functioning as a subsidiary of Stevanato Holding S.R.L.
STVN Company Deck
STVN Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted strong top-line growth, robust Biopharmaceutical & Diagnostic Solutions momentum (notably syringes, biologics and GLP1 exposure), expanding high-value solution mix, margin expansion on an adjusted basis, and clear progress on strategic capacity investments. Offsetting these positives were a sharp revenue decline in the Engineering segment, segment-level gross margin compression for BDS driven by ramp-related depreciation, FX and tariff headwinds, a higher tax rate, modest free cash flow in the quarter due to heavy growth capex, and slower order conversion cycles in Engineering. Management reiterated full-year guidance and emphasized demand-driven capacity investment and operational optimization.View all STVN earnings summariesSTVN Stock 12 Month Forecast
Average Price Target
$22.00
▲(41.66% Upside)
Technical Analysis
Ownership Overview
2.77% Insiders
43.39% Mutual Funds
2.19% Other Institutional Investors
49.47% Public Companies and
Individual Investors